Harrow Inc., a leading North American eyecare pharmaceutical company, has appointed Mike Biega as Vice President of Investor Relations and Communications. Biega succeeds Jamie Webb, who is retiring, and will remain in her role until August to ensure a smooth transition. Biega brings over a decade of experience in biotech investor relations, having previously served as Sr. Director, Head of Investor Relations at Sensei Biotherapeutics.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.